Dong-A looks to future with new drugs

Published: 2009-10-23 06:57:00

Updated: 2009-10-23 06:57:00

The two drug candidates of Dong-A Pharmaceutical Co. are expected to bolster its stock prices in the near future, according to market analysts.

The company said that its pipeline drugs - functional dyspepsia drug (DA-9701) and anti-infective agent (DA-7218) – are now under Phase 3 clinical tri...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK